MondegarAI
Pivotal bioVenture Partners Investment Advisor LLC

Q4 2024 · 13F-HR

Pivotal bioVenture Partners Investment Advisor LLCholdings as filed

Filed 2025-02-13 · accession 0001012975-25-000081

$148.1M
Reported value
11
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
92243G108PCVXVAXCYTE INC$57.6M38.9%703,834CommonSHARED
H5870P102OCSOCULIS HOLDING AG$29.5M20.0%1,737,696CommonSHARED
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$29.5M19.9%2,120,508CommonSHARED
45790W108INOZYME PHARMA INC$12.5M8.41%4,494,851CommonSHARED
98937L105ZBIOZENAS BIOPHARMA INC$6.0M4.07%736,645CommonSHARED
75629V104RXRXRECURSION PHARMACEUTICALS IN$4.0M2.72%595,518CommonSHARED
09077V100BIOABIOAGE LABS INC$3.8M2.55%653,374CommonSHARED
75120L100RALLYBIO CORP$2.3M1.56%2,404,644CommonSHARED
097702104BOLT1EURBOLT BIOTHERAPEUTICS INC$1.0M0.69%1,891,467CommonSHARED
92673K108VIGLVIGIL NEUROSCIENCE INC$953,0120.64%560,595CommonSHARED
449778109IOBTQIO BIOTECH INC$795,0610.54%864,197CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.